231 related articles for article (PubMed ID: 17584152)
1. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Atanasov AG; Odermatt A
Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):125-40. PubMed ID: 17584152
[TBL] [Abstract][Full Text] [Related]
2. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
6. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Oppermann U
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
[TBL] [Abstract][Full Text] [Related]
7. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
8. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
11. The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.
Odermatt A; Nashev LG
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):1-13. PubMed ID: 20100573
[TBL] [Abstract][Full Text] [Related]
12. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
13. 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.
Chapman KE; Seckl JR
Neurochem Res; 2008 Apr; 33(4):624-36. PubMed ID: 17963039
[TBL] [Abstract][Full Text] [Related]
14. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
[TBL] [Abstract][Full Text] [Related]
15. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
[TBL] [Abstract][Full Text] [Related]
17. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Seckl JR; Walker BR
Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
19. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.
Wu L; Qi H; Zhong Y; Lv S; Yu J; Liu J; Wang L; Bi J; Kong X; Di W; Zha J; Liu F; Ding G
Endocr J; 2013; 60(9):1047-58. PubMed ID: 23759754
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
